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Background: Nonalcoholic fatty liver disease (NAFLD) is an escalating medical problem worldwide. A
nonsynonymous single nucleotide polymorphism rs738409 (I148M) in patatin-like phospholipase domain-containing
protein 3 (PNPLA3) predisposes susceptibility to NAFLD; however, its association with steatosis grade is inconsistent
in the literature. In particular, there was no significant association found between I148M and steatosis grade in two
East Asian-based studies. In this study we aim to investigate whether I148M is associated with the
ultrasonography-determined steatosis degree in Chinese adults.
Methods: 203 NAFLD cases and 202 matched controls were recruited. Cases were classified into mild, moderate
and severe fatty liver by ultrasonography. Association between I148M and the ultrasonography-determined
steatosis degree as well as other clinical parameters was evaluated.
Results: The I148M variant was associated with the ultrasonography-determined steatosis degree with the M allele
frequencies being 0.32, 0.54, and 0.87 in mild (n=105), moderate (n=83), and severe (n=15) cases, respectively
(P–value = 7.6×10-8). We also confirmed the interaction between I148M variation and body mass index towards
elevated plasma alanine aminotransferase levels in cases (P–value = 4.4×10-4).
Conclusion: The PNPLA3 I148M variant is associated with the ultrasonography-determined steatosis degree in
Chinese population.
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Nonalcoholic fatty liver disease (NAFLD) is an escalating
medical problem worldwide. It affects 20-34% of the
population in Western countries [1]; although the preva-
lence of NAFLD is somewhat lower in East Asia—25%
in Japan [2], 18% in South Korea [3], and 15% in China
[4]—its incidence has increased rapidly with a growing
prevalence in young generations during the last two
decades [5,6].
NAFLD is a multifactorial disorder associated with obes-
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reproduction in any medium, provided the or[1,7]. Familial clustering of steatosis, nonalcoholic steato-
hepatitis, and cryptogenic cirrhosis suggests that genetic
factors contribute to the susceptibility to NAFLD [8,9].
Multiple genes have been reported to be associated
with NAFLD by candidate gene studies (for a review see
[10]), and, more recently, by genome-wide association
studies [11-13]. A nonsynonymous sequence variation
(rs738409) in patatin-like phospholipase domain-containing
protein 3 (PNPLA3) that substitutes methionine for
isoleucine at residue 148 (I148M) was first reported to
be associated with hepatic triglyceride content in a
genome-wide screen [11]; subsequently its association
with NAFLD was confirmed in multiple ethnic and geo-
graphic groups (for a review see [14]) including the East
Asian populations [15-19]. The I148M variant was also
reported to be associated with the histological severity of
NAFLD (for a review see [20]); however, in two Easthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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between I148M and steatosis stage [15,16]. In particular,
in a sample of 112 Chinese NAFLD patients I148M was
found to be associated with fibrosis but not steatosis
grade [16]. In this study we investigated the association
between I148M and the ultrasonography-determined
steatosis degree in a larger collection of Chinese NAFLD
patients.
Although the PNPLA3 I148M variant is not associated
with body-mass-index (BMI) in the general population
[11,13], it was shown that morbid obesity exposed the
association between the 148M allele and plasma alanine
aminotransferase (ALT) levels in both obese adults [21]
and children [22,23]. Further it was shown in obese chil-
dren the association between I148M and ALT levels was
due to the interaction with abdominal fat [24]. More re-
cently it was shown the 148M allele interacted with
obesity towards type 2 diabetes susceptibility [25]. In this
study we also attempted to replicate the interaction be-
tween I148M and BMI on ALT levels and to investigate
whether it contributes to NAFLD susceptibility.Methods
A total of 203 unrelated adults with NAFLD were
recruited from an outpatient liver clinic at the First
Affiliated Hospital of China Medical University in Shen-
yang, China, between October 2010 and April 2011. The
patients were confirmed to have hepatic steatosis by liver
ultrasonography and classified into three categories—mild,
moderate, and severe—according to established criteria
[26]. In particular, five criteria were used to diagnose
NAFLD: 1) diffuse enhancement of near field echo in the
hepatic region and gradual attenuation of the far field
echo; 2) unclear display of intra-hepatic lacuna structure;
3) mild to moderate hepatomegaly with a round blunt
border; 4) reduction of blood flow signal in the liver; and
5) unclear or non-intact display of envelop of right liver
lobe and diaphragm. Patients meeting criterion 1 and any
one of criteria 2-4 were classified as mild; patients meeting
criterion 1 and any two of criteria 2-4 were classified as
moderate; and patients meeting criteria 1, 5, and any two
of criteria 2-4 were classified as severe [26]. All the exami-
nations were performed by one experienced radiologist,
who was unaware of the patients’ clinical details and la-
boratory findings, using a GE Vivid7 ultrasound machine
(GE Healthcare, Horten, Norway) equipped with a GE 4C
curved array transducer (GE H4904PC). Secondary causes
of steatosis—ethanol intake, total parenteral nutrition,
hepatitis B and Hepatitis C virus, autoimmune liver dis-
ease, hemochromatosis, alpha1-antitrypsin deficiency,
Wilson’s disease, use of drugs that promote steatosis—
were ruled out. A total of 202 ethnicity-matched controls
with normal liver enzyme levels and no steatosis byultrasonography were recruited from primary care out-
patient clinics at the same institution. Written informed
consent was obtained using a protocol approved by the
ethics committee of the First Affiliated Hospital of China
Medical University.
Age and sex were self-reported. BMI was calculated
according to the measured height and weight at the time
of recruitment. Venous blood samples were obtained
from the subjects after an overnight fast (12 hours).
Plasma ALT, aspartate aminotransferase (AST), γ-
glutamyltransferase (GGT), fasting blood glucose (FBG),
triglycerides, high density lipoprotein cholesterol
(HDL-C) and low density lipoprotein cholesterol (LDL-C)
levels were measured using an automated analyzer.
Genomic DNA was extracted from leukocytes using
AxyPrep Whole Blood Genomic DNA Miniprep Kit
(Axygen Biosciences, USA). The I148M variant was
genotyped using a TaqMan assay on a 7900HT Fast
Real-Time PCR instrument (Applied Biosystems, Foster
City, CA) at 50°C for 2 min, 95°C for 10 min, and then
40 cycles of 95°C for 15 sec and 60°C for 1.5 min.
Hardy-Weinberg equilibrium (HWE) was examined by
Pearson’s χ2 goodness-of-fit test in cases and controls,
respectively.
Comparisons of demographic and clinical features
between cases and controls were performed by a two-
sample t-test for continuous variables and by a propor-
tion test for categorical variables. Comparisons between
caterogies of cases were performed by analysis of vari-
ance. Linear regression models were fit to test associ-
ation between genotype and continuous phenotypes, and
logistic regression models were fit to test association be-
tween genotype and categorical phenotype. Bonferroni
correction was performed to correct for multiple test-
ing. The genotypic value was coded in an additive man-
ner, i.e., 0, 1, and 2 denoted II, IM, and MM genotypes,
respectively. The interaction between I148M and BMI
for a continuous trait—ALT—was tested by examining
the interaction term in a linear regression model; the
interaction for an ordinal trait—the ultrasonography-
determined steatosis degree—was tested by examining
the interaction term in an ordered logistic regression
model; the interaction for a binary trait—NAFLD—was
tested either by examining the interaction term in a
logistic regression model using both cases and controls,
or by examining the association between I148M and
BMI using only cases. We estimated the power to detect
interaction a priori given the sample size; when there
was no significant interaction detected, we also esti-
mated sample sizes required to achieve the power of 0.8.
The power analyses were performed for a quantitative
trait [27] and for a binary trait in both case-control
[28,29] and case-only [30] designs. All analyses were
performed using R [31] except that power analysis in
Li et al. BMC Medical Genetics 2012, 13:113 Page 3 of 6
http://www.biomedcentral.com/1471-2350/13/113a case-control design was performed using POWER
V3.0 [28,29].
Results
The comparisons of demographic, clinical, and genetic
characteristics between the 203 NAFLD cases and 202
controls were reported elsewhere [17]. Here we fo-
cused on comparing the characteristics among cases
with the different ultrasonography-determined steato-
sis degrees, as summarized in Table 1. Based on liver
ultrasonography the 203 NAFLD cases were classified
into three categories—mild degree (n = 105), moderate
degree (n = 83), and severe degree (n = 15). The 15 se-
vere cases were on average younger than the mild and
moderate cases (38.9 ± 13.9 years versus 47.6 ± 13.3
and 47.4 ± 13.2 years, respectively). BMI increased
with the ultrasonography-determined steatosis degree
(P < 0.01). Liver enzyme levels ALT and AST increased
with the steatosis degree (P-values < 0.01) whereas
GGT levels did not (P > 0.10). Triglycerides levels
showed a marginal increase with the increase of the
steatosis degree (nominal P-value = 0.03), whereas
LDL-C and HDL-C levels did not (P-values > 0.10).
FBG levels were higher in the 15 severe cases, though
not statistically significant (P-value > 0.10).
The distribution of the I148M variant in cases and
controls was summarized in Table 2. In controls it
was in HWE (P-value=0.59), which guaranteed theTable 1 Demographic, clinical, and genetic characteristics
of NAFLD cases stratified by the ultrasonography-
determined steatosis degree†
Variable Steatosis grade P-value‡
Mild Moderate Severe
Sample size 105 83 15
Age (years) 47.6 ± 13.3 47.4 ± 13.2 38.9 ± 13.9 0.06
BMI (kg/m2) 26.1 ± 3.7 27.2 ± 4.4 30.5 ± 5.3 < 0.01
ALT (IU/L) 30.9 ± 21.3 50.1 ± 36.1 106.3 ± 78.5 < 0.01
AST (IU/L) 28.8 ± 26.9 29.5 ± 13.4 59.8 ± 62.46 < 0.01
GGT (IU/L) 63.0 ± 83.8 55.8 ± 48.6 78.2 ± 47.7 > 0.10
Triglycerides (mmol/L) 1.8 ± 1.3 2.3 ± 1.5 2.4 ± 1.8 0.03
LDL-C (mmol/L) 3.4 ± 1.0 3.3 ± 1.1 3.1 ± 1.2 > 0.10
HDL-C (mmol/L) 1.3 ± 0.4 1.4 ± 0.8 1.1 ± 0.2 > 0.10
FBG (mmol/L ) 6.0 ± 1.3 6.0 ± 1.1 6.7 ± 1.9 > 0.10
PNPLA3-I148M
II 52 18 0 7.6×10-8
IM 39 41 4
MM 14 24 11
†Data are described by mean ± standard deviation for continuous variables.
‡For demographic and clinical variables nominal P-values were calculated by
an F-test using ANOVA; for I148M the P-value was calculated by Fisher’s exact
test. P-values for BMI, ALT, and AST remained < 0.01 after Bonferroni multiple
testing correction (9 tests).genotyping quality, but in cases it was out of HWE
(P-value=0.02), which indicated its association with the
disease status [32]. We previously showed the I148M
variant was associated with the NAFLD affection status
with the minor allele M being more frequent in cases
than in controls (0.45 versus 0.31; P-value=1.5×10-4)
[17]. This variant was also associated with the
ultrasonography-determined steatosis degree with the M
allele frequencies being 0.32, 0.54, and 0.87 in mild,
moderate, and severe cases, respectively (P–value =
7.6×10-8). We further investigated the association be-
tween I148M and other clinical parameters in cases and
controls, respectively (Table 2). In cases, as the copy
number of M allele increased, ALT levels significantly
increased (nominal P–value = 1.1×10-7, Bonferroni
corrected P–value = 2.0×10-6), and AST showed a ten-
dency of increase but not statistically significant (nominal
P–value = 0.07), whereas LDL-C levels showed a tendency
of decrease (nominal P–value = 4.1×10-3; Bonferroni cor-
rected P–value = 7.4×10-2). None of the clinical features
were significantly associated with I148M in controls.
There was no statistically significant association be-
tween I148M and BMI in either cases or controls, or the
combined sample (P-values > 0.10). Therefore we inves-
tigated their interaction towards ALT levels and NAFLD
susceptibility assuming independence between them.
Given the allele frequency of I148M variant in cases and
the distributions of ALT levels and BMI in each geno-
typic category, the power to detect a significant inter-
action between I148M and BMI at the level of 0.05 was
greater than 0.99 [27], and we did detect an interactive
effect between them towards elevated ALT levels in
cases (P–value = 4.4×10-4) by a linear regression model.
Stratifying the cases into quarters by BMI, it showed the
MM genotype interacted with high BMI to elevate ALT
levels (Figure 1). The power to detect an intercation
between I148M and BMI towards NAFLD susceptibility
was estimated to be 0.12 for a case-control design
[28,29] and 0.20 for a case-only design [30], respectively,
and we did not detect any significant interaction given
the data (P-values > 0.10). To detect a significant inter-
action at the level of 0.05 with a power of 0.8, it would
need a sample size of either 2,362 cases or 1,316 cases
and 1,316 controls. There was no significant interac-
tion between I148M and BMI towards elevated AST
levels or the ultrasonography-determined steatosis
degree (P-values > 0.10).
Discussion
It is well recognized the PNPLA3 I148M variant predis-
poses susceptibility to NAFLD and it is associated with
the histological severity of NAFLD. However, some stud-
ies showed it was associated with steatosis grade [33-37],
whereas in two East Asian-based studies, there was no
Table 2 Association between PNPLA3 I148M and clinical parameters in NAFLD cases and controls†
Variable Cases P-value‡ Controls P-value‡
II (n=70) IM (n=84) MM (n=49) II (n=94) IM (n=90) MM (n=18)
Age (years) 47.6 ± 13.3 46.9 ± 13.3 45.8 ± 14.3 > 0.10 40.2 ± 12.8 42.7 ± 12.9 46.6 ± 14.7 0.04
BMI (kg/m2) 26.8 ± 4.4 27.1 ± 5.3 26.7 ± 5.3 > 0.10 23.0 ± 3.1 23.8 ± 3.9 24.2 ± 2.9 > 0.10
ALT (IU/L) 32.2 ± 22.5 38.2 ± 28.1 72.2 ± 59.0 1.1×10-7 17.4 ± 9.2 16.5 ± 7.1 17.5 ± 5.6 > 0.10
AST (IU/L) 28 ± 20.7 30.7 ± 23.8 37.5 ± 40.5 0.07 19.9 ± 4.8 19.7 ± 3.8 19.3 ± 3.6 > 0.10
GGT (IU/L) 73.1 ± 52.1 56.1 ± 58.2 52.8 ± 46.6 > 0.10 25.3 ± 17.1 24.5 ± 16.0 23.4 ± 12.9 > 0.10
Triglycerides (mmol/L) 1.9 ± 1.3 2.2 ± 1.5 2.0 ± 1.4 > 0.10 1.0 ± 0.5 1.1 ± 0.5 1.2 ± 0.4 > 0.10
LDL-C (mmol/L) 3.6 ± 1.2 3.4 ± 0.9 3.0 ± 1.0 4.1×10-3 2.5 ± 1.1 2.6 ± 1.1 2.8 ± 1.2 > 0.10
HDL-C (mmol/L) 1.3 ± 0.5 1.3 ± 0.7 1.4 ± 0.6 > 0.10 1.9 ± 0.8 1.9 ± 1.0 2.0 ± 1.1 > 0.10
FBG (mmol/L ) 6.0 ± 1.1 6.1 ± 1.5 6.0 ± 1.1 > 0.10 5.5 ± 1.3 5.6 ± 1.4 5.9 ± 0.9 > 0.10
†Data are described by mean ± standard deviation.
‡Nominal P-values were calculated by fitting linear regression models, in which Age and BMI were adjusted for when testing other variables. After Bonferroni
multiple testing correction (18 tests), the only significant association was between ALT levels and genotype in cases (adjusted P-value = 2.0×10-6).
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I148M was associated with fibrosis progression in both
studies. In this study we reported a positive associa-
tion result between I148M and the ultrasonography-
determined steatosis grade in an East Asian population.
One major limitation of this study is that the steatosis
grade was assessed based on ultrasonography instead of
liver biopsy, which represents the best diagnostic test for
fatty liver diseases. In this study, the steatosis degree was
graded by an experienced hepatologist according to
















BMI ≤ 24.4 ≤ 26.6
N 22 15 14 14 18 16
Figure 1 Interaction between PNPLA3 I148M and BMI towards elevate
by BMI; in each quarter cases were further stratified by the I148M genotype88% in the diagnosis and staging of fatty liver from a dir-
ect comparison between the pathological and ultrasono-
graphic findings [38]. Thus the association between
I148M and the ultrasonography-determined steatosis de-
gree was unlikely false positive due to technology
limitations.
Plasma liver-enzyme levels are widely used as indica-
tors of liver damage and they are influenced by environ-
mental and genetic factors. ALT levels were shown to be
associated with the PNPLA3 I148M variant [11,39,40],
and we replicated this association in cases but not in≤ 29.3 > 29.3 kg m
2
14 31 8 20 20 11
d ALT levels in NAFLD cases. Cases were first stratified into quarters
, and in each group the median of ALT levels was plotted.
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controls (Table 2), which partially explained the differ-
ence of the association results. We did not merge cases
and controls together for an association test because of
heteroscedasticity.
Although the association of PNPLA3 with hepatic fat
content and liver function is well established, its involve-
ment in lipoprotein metabolism remains indeterminate.
In this study the 148M allele was associated with
reduced LDL-C levels in the NAFLD patients (nominal
P–value = 4.1×10-3); when the ALT levels were adjusted
for, the association became more significant (P–value =
3.6×10-3). This result was consistent with that in another
large study [41], implying the association between
I148M and LDL-C levels was not simply a consequence
of liver function impairment. In silico bioinformatic ana-
lysis suggested that PNPLA3 be involvoed in the metab-
olism of apoB-containing lipoproteins [41]. Although
in vitro experiments suggested that PNPLA3 be involved
in triglycerides metabolism [11,42], there was no associ-
ation between I148M and triglycerides either in normal
populations [11] or in our NAFLD cases (P–value > 0.10).
However, there were reports on their association in obese
populations [25,41]. We speculate that I148M interacts
with BMI / body fat distribution on triglyceride levels.
It is intriguing to investigate whether metabolic
comorbidities such as obesity and insulin resistance,
which are associated with the pathogenesis of NAFLD,
are also influenced by the PNPLA3 I148M variant. There
was no significant association between I148M and BMI
in either cases or controls, consistent with the results in
general populations [11,13]. It was suggested that body
fat distribution, in particular abdominal fat, be impli-
cated in the risk of developing NAFLD [43]. There were
studies showing interaction between I148M and obesity
parameters (BMI and waist circumference) on ALT
levels [21,24] and type 2 diabetes susceptibility [25]. In
this study we observed that the MM genotype interacted
with high BMI to elevate ALT levels in cases; however,
their interaction towards NAFLD susceptibility was in-
significant by either a case-only or a case-control study.
Larger sample studies are needed to investigate whether
this interaction contributes to NAFLD susceptibility and
triglyceride levels.
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